These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30055340)

  • 1. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen.
    Crabtree NJ; Adams JE; Padidela R; Shaw NJ; Högler W; Roper H; Hughes I; Daniel A; Mughal MZ
    Bone; 2018 Nov; 116():181-186. PubMed ID: 30055340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cessation of ambulation results in a dramatic loss of trabecular bone density in boys with Duchenne muscular dystrophy (DMD).
    Crabtree NJ; Roper H; Shaw NJ
    Bone; 2022 Jan; 154():116248. PubMed ID: 34718220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
    Ma J; McMillan HJ; Karagüzel G; Goodin C; Wasson J; Matzinger MA; DesClouds P; Cram D; Page M; Konji VN; Lentle B; Ward LM
    Osteoporos Int; 2017 Feb; 28(2):597-608. PubMed ID: 27774565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
    Suthar R; Reddy BVC; Malviya M; Sirari T; Attri SV; Patial A; Tageja M; Didwal G; Khandelwal NK; Saini AG; Saini L; Sahu JK; Dayal D; Sankhyan N
    J Pediatr Endocrinol Metab; 2021 May; 34(5):573-581. PubMed ID: 33838091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy.
    Mayo AL; Craven BC; McAdam LC; Biggar WD
    Neuromuscul Disord; 2012 Dec; 22(12):1040-5. PubMed ID: 22824639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
    Zhou L; Zhou H; Xu H; Sun X; Chen X; Fan P; Cai X; Wang Q
    Osteoporos Int; 2024 Jun; 35(6):997-1005. PubMed ID: 38277031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
    Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Smit K; Walker S; Hartigan C; Khan N; Konji VN; MacLeay L; Page M; Sykes E; Robinson ME; Alos N; Cummings EA; Ho J; Sbrocchi AM; Stein R; Saleh D; Craven BC; Dang UJ; Siminoski K; Rauch F; Ward LM
    Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.
    Joseph S; Wang C; Bushby K; Guglieri M; Horrocks I; Straub V; Ahmed SF; Wong SC;
    JAMA Neurol; 2019 Jun; 76(6):701-709. PubMed ID: 30855644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
    Moretti A; Liguori S; Paoletta M; Gimigliano F; Iolascon G
    Adv Ther; 2022 Jul; 39(7):3308-3315. PubMed ID: 35614293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy.
    Ricotti V; Ridout DA; Scott E; Quinlivan R; Robb SA; Manzur AY; Muntoni F;
    J Neurol Neurosurg Psychiatry; 2013 Jun; 84(6):698-705. PubMed ID: 23250964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Testosterone Treatment for Delayed Puberty in Duchenne Muscular Dystrophy.
    Lee SL; Lim A; Munns C; Simm PJ; Zacharin M
    Horm Res Paediatr; 2020; 93(2):108-118. PubMed ID: 32610327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy.
    Kao KT; Joseph S; Capaldi N; Brown S; Di Marco M; Dunne J; Horrocks I; Shepherd S; Ahmed SF; Wong SC
    Eur J Pediatr; 2019 May; 178(5):633-640. PubMed ID: 30762116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone microarchitectural alterations in boys with Duchenne muscular dystrophy on long-term glucocorticoid treatment.
    Tung JY; Lam TP; Chan SH
    J Bone Miner Metab; 2021 Jul; 39(4):606-611. PubMed ID: 33400004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Factors Associated with Incident Vertebral Fractures in Steroid-treated Males with Duchenne Muscular Dystrophy.
    Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Wilson N; Walker S; Hartigan C; Khan N; Page M; Robinson ME; Saleh DS; Smit K; Rauch F; Siminoski K; Ward LM
    J Clin Endocrinol Metab; 2024 Jan; 109(2):536-548. PubMed ID: 37610420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy.
    Hawker GA; Ridout R; Harris VA; Chase CC; Fielding LJ; Biggar WD
    Arch Phys Med Rehabil; 2005 Feb; 86(2):284-8. PubMed ID: 15706555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fractures and bone health monitoring in boys with Duchenne muscular dystrophy managed within the Scottish Muscle Network.
    Joseph S; Wang C; Di Marco M; Horrocks I; Abu-Arafeh I; Baxter A; Cordeiro N; McLellan L; McWilliam K; Naismith K; Stephen E; Ahmed SF; Wong SC
    Neuromuscul Disord; 2019 Jan; 29(1):59-66. PubMed ID: 30473133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
    Singh A; Schaeffer EK; Reilly CW
    J Pediatr Orthop; 2018 Jul; 38(6):320-324. PubMed ID: 27328118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates.
    Catalano A; Vita GL; Bellone F; Sframeli M; Distefano MG; La Rosa M; Gaudio A; Vita G; Morabito N; Messina S
    J Endocrinol Invest; 2022 Mar; 45(3):517-525. PubMed ID: 34524678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth pattern trajectories in boys with Duchenne muscular dystrophy.
    Stimpson G; Raquq S; Chesshyre M; Fewtrell M; Ridout D; Sarkozy A; Manzur A; Ayyar Gupta V; De Amicis R; Muntoni F; Baranello G;
    Orphanet J Rare Dis; 2022 Jan; 17(1):20. PubMed ID: 35073949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.